Humoral Response to Influenza Vaccination in HIV-Infected Patients
- First Online:
- 8 Downloads
Objective: To assess the humoral response in HIV-infected adults immunised against influenza in Poland in the epidemic season 1997/98.
Patients and Methods: The study was carried out in 34 HIV-infected patients in different stages of the disease, vaccinated with a single 0.5ml dose of subunit vaccine (‘Influvac’, Solvay Pharmaceuticals BV). Antihaemagglutinin (HI) antibody levels were measured by the haemagglutinin inhibition test before immunisation and then after one and six months.
Results: One month after vaccination HI antibody titres significantly increased from 1.5 to 5.5 times. After six months HI antibody levels were higher than those before vaccination and also higher than those determined one month after vaccination. Before immunisation the number of patients with HI antibody titres ≥l:40 ranged from 2.9 to 50%. After vaccination, protection rates increased and ranged from 17.6 to 79.4% one month after vaccination, and from 20.6 to 82.4% six months after vaccination. Response rate values remained at similar levels during the whole study and were between 9.4 and 14.7%. No statistically significant differences were found in humoral response between patients with different CD4 counts nor between AIDS patients and those not suffering from AIDS. Significantly higher antibody titres were recorded during the whole study for the A/Wuhan/359/95 (H3N2) influenza strain than for the A(H1N1) and B strains.
Conclusions: The results of this study indicated that in HIV-infected patients humoral response to influenza vaccination was poor compared with healthy people. However, in some HIV-infected patients the vaccine induced the production of HI antibodies in titres that were considered high enough to protect against the infection.
Unable to display preview. Download preview PDF.
- 1.Brydak LB, editor. Influenza and its prophylaxis. Warsaw: Springer PWN, 1998Google Scholar
- 2.Brydak LB. Influenza vaccination policy in Poland. European Scientific Working Group on Influenza. Information and news on influenza. Influenza Bulletin 1998; 9: 7–8Google Scholar
- 3.Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998; 47(RR-6): 4–7Google Scholar
- 6.Cohn D. Bacterial pneumonia in the HIV-infected patients. Infect Dis Clinic North Am 1991; 5: 485–507Google Scholar
- 12.Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morbid Mortal Wkly Rep 1992; 41(RR-17): 1–19Google Scholar
- 16.Brydak LB, Rokicka-Milewska R, Machala M, et al. Studies on the humoral immune response to hemagglutinin of influenza vaccine in children with acute lymphoblastic leukemia after chemotherapy treatment. Int J Pediatr Hematol/Oncol. In pressGoogle Scholar
- 17.Brydak L, Rokicka-Milewska R, Klukowska A, et al. Antibody kinetics in children with hemophilia immunized with influenza vaccine in 1993 in Poland. Int J Pediatr Hematology/ Oncology 1998; 5(1): 13–9Google Scholar
- 18.Brydak LB, Rajkowski T, Machala M, et al. Humoral antibody response following influenza vaccination in patients with nephrotic syndrome. Antiinfect Drugs Chemother 1998; 16(2): 151–5Google Scholar
- 20.Birx DL, Rhoads JL, Wright JC, et al. Immunologic parameters in early stage HIV-seropositive subjects associated with vaccine responsiveness. J Acquir Immun Defic Syndr 1991; 4: 188–96Google Scholar
- 24.Brydak L, Ordyñska E, Wasilewski B, et al. Immunogenicity of trivalent subunit influenza vaccine in elderly people with chronic medical conditions vaccinated in 1993 in Poland. Antiinfect Drugs Chemother 1997; 15(1): 9–12Google Scholar
- 26.Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (revision). 1997 Mar 12: CPMP/BWP/214/96Google Scholar
- 27.Commission of the European Communities. The rules governing medicinal products in the European Community. Commission Eur Commun 1992; 3(2): 93–8Google Scholar